XENE Jul 2024 35.000 put
| Previous close | 1.9500 |
| Open | 1.9500 |
| Bid | 0.5000 |
| Ask | 2.3500 |
| Strike | 35.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.9500 - 1.9500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireXenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are excited that our abstracts focused on XEN1101, including interim data from the ongoing X-TOLE open-label extension st
- GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference taking place April 16-17, 2024. Company Presentation Details:Date: Tuesday, April 16, 2024Time: 9:30 AM Eastern TimeWebcast: Register herePresenters: Ian Mortimer, President and Chief Executive Officer A live webcast of the company present
- GlobeNewswire
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 23rd Annual Needham (Virtual) Healthcare Conference taking place April 8-11, 2024. Company Fireside Chat Presentation Details: Date:Thursday, April 11, 2024 Time:3:00 PM Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive Officer Sherry Aulin, Chief Financ
